Personalized tumor-informed circulating tumor DNA monitoring for early detection of recurrence in postoperative pancreatic cancer

BackgroundUp to 80% of patients with resected pancreatic cancer experience recurrence within 2 years. We evaluated the feasibility and accuracy of a personalized, tumor-informed circulating tumor DNA (ctDNA) test for the early detection of recurrence risk during long-term postoperative surveillance....

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Jingjing Chen, Lu Zou, Xinyuan Bai, Fan Tong, Jiayao Ni, Haochen Tang, Yaru Liu, Xiang Kong, Jiani Yin, Fufeng Wang, Huizi Sha, Fanyan Meng, Juan Du
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Frontiers Media S.A. 2026-01-01
Цуврал:	Frontiers in Oncology
Нөхцлүүд:	adjuvant chemotherapy circulating tumor DNA dynamic ctDNA minimal residual disease pancreatic cancer
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1745466/full
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!